研究業績

• Curriculum vitae (PDF)

Publications (Peer-Reviewed)

Statistical Methodology and Applications in Biostatistics

1. Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven BPL, Tsushima T, Takeuchi H, Kato K, Kitagawa Y. Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable esophageal cancer. British Journal of Surgery 2025;112(6): znaf131. DOI: 10.1093/bjs/znaf131. [Software]
2. Kondo M, Nagashima K, Isono S, Sato Y. Weighted repeated measures correlation coefficient: A new correlation coefficient for handling missing data with repeated measures. Statistics in Medicine 2025;44(10–12): e70046. DOI: 10.1002/sim.70046.
3. Gosho M, Ishii R, Nagashima K, Noma H, Maruo K. Determining the prior mean in Bayesian logistic regression with sparse data: A non-arbitrary approach. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2025;74(1): 126–141. DOI: 10.1093/jrsssc/qlae048.
4. Kimura R, Nomura S, Nagashima K, Sato Y. Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method. BMC Medical Research Methodology 2024;24(1):166. DOI: 10.1186/s12874-024-02295-2.
5. Gosho M, Ohigashi T, Nagashima K, Ito Y, Maruo K. Bias in odds ratios from logistic regression methods with sparse data set. Journal of Epidemiology 2023;33(6):265–275. DOI: 10.2188/jea.JE20210089.
6. Noma H, Nagashima K, Kato S, Teramukai S, Furukawa TA. Flexible random-effects distribution models for meta-analysis. Journal of Epidemiology 2022;32(10):441–448. DOI: 10.2188/jea.JE20200376. [arXiv:2003.04598]
7. Hamaguchi Y, Noma H, Nagashima K, Yamada T, Furukawa TA. Frequentist performances of Bayesian prediction intervals for random-effects meta-analysis. Biometrical Journal 2021;63(2):394–405. DOI: 10.1002/bimj.201900351. [arXiv:1907.00345]
8. Nagashima K, Noma H, Sato Y, Gosho M. Sample size calculations for single-arm survival studies using transformations of the Kaplan–Meier estimator. Pharmaceutical Statistics 2021;20(3):499–511. DOI: 10.1002/pst.2090. [arXiv:2012.03355]
9. Noma H, Nagashima K, Furukawa TA. Permutation inference methods for multivariate meta-analysis. Biometrics 2020;76(1):337–347. DOI: 10.1111/biom.13134. [arXiv:1809.03935]
10. Nagashima K, Noma H, Furukawa TA. Prediction intervals for random-effects meta-analysis: a confidence distribution approach. Statistical Methods in Medical Research 2019;28(6):1689–1702. DOI: 10.1177/0962280218773520. [arXiv:1804.01054] [Software]
11. Noma H, Nagashima K, Maruo K, Gosho M, Furukawa TA. Bartlett-type corrections and bootstrap adjustments of likelihood-based inference methods for network meta-analysis. Statistics in Medicine 2018;37(7):1178–1190. DOI: 10.1002/sim.7578.
12. Gosho M, Sato Y, Nagashima K, Takahashi S. Trends in study design and the statistical methods employed in a leading general medicine journal. Journal of Clinical Pharmacy and Therapeutics 2018;43(1):36–44. DOI: 10.1111/jcpt.12605.
13. Sato Y, Gosho M, Nagashima K, Takahashi S, Ware JH, Laird NM. Statistical methods in the Journal — an update. New England Journal of Medicine 2017;376(11):1086–1087. DOI: 10.1056/NEJMc1616211. (Correspondence)
14. Nagashima K, Sato Y. Information criteria for Firth's penalized partial likelihood approach in Cox regression models. Statistics in Medicine 2017;36(21):3422–3436. DOI: 10.1002/sim.7368. [Postprint]
15. Noma H, Nagashima K. A note on the Mantel–Haenszel estimators when the common effect assumptions are violated. Epidemiologic Methods 2016;5(1):19–35. DOI: 10.1515/em-2015-0004.
16. Nagashima K, Sato Y, Noma H, Hamada C. An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach. Statistics in Medicine 2013;32(27):4838–4858. DOI: 10.1002/sim.5895. [arXiv:1805.05017]
17. Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker research. Sensors 2012;12(7):8966–8986. DOI: 10.3390/s120708966. (Review)
18. Nagashima K, Sato Y, Hamada C. A modified maximum contrast method for unequal sample sizes in pharmacogenomic studies. Statistical Applications in Genetics and Molecular Biology 2011;10(1):Article 41. DOI: 10.2202/1544-6115.1560. [arXiv:2012.03475] [Software]
19. Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim S-R, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada J-i, Yoshida T. A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. The Pharmacogenomics Journal 2009;9(2):137–146. DOI: 10.1038/tpj.2008.17.

Medical Researches

20. Yamaoka K, Katsumata Y, Kohsaka S, Shiraishi Y, Kondo M, Nagashima K, Onoue T, Kataoka M, Watanabe T, Nakashima D, Muramoto Y, Sato Y, Sato K, Nakamura M, Ieda M. Patient-centered medical tools for sustained motivation in cardiac rehabilitation of patients with heart failure: protocol of a multicenter randomized controlled trial (EXERCISE-HF trial). Contemporary Clinical Trials Communications 2025. In press. DOI: 10.1016/j.conctc.2025.101522.
21. Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M, Tsuruoka N, Kasai T, Hata A. Ripple effect of temporary self-sampling HPV test on screening uptake in the next round: A secondary analysis of the ACCESS randomized controlled trial. Journal of Medical Screening 2025. In press. DOI: 10.1177/09691413251352999.
22. Nagoshi N, Nagashima K, Okubo T, Ozaki M, Suzuki S, Takeda K, Iga T, Matsumoto M, Nakamura M, Watanabe K. How many cases of spinal intramedullary ependymoma surgery are required to achieve stability? - Analysis using X-bar charts. Spinal Cord 2025;63(7):372–376. DOI: 10.1038/s41393-025-01090-0.
23. Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Takeuchi M, Hirata K, Tsugaru K, Yamamoto S, Nomura M, Tsushima T, Takeuchi H, Kato K, Kitagawa Y. Investigating the synergistic effects of pembrolizumab and chemotherapy in gastric and gastroesophageal junction cancer. Journal of Gastric Cancer 2025;25(3):455–465. DOI: 10.5230/jgc.2025.25.e33.
24. Hasegawa Y, Itokawa N, Kashiro A, Kitamura M, Nagashima K, Suzuki K, Higashi T, Shioda-Koyano K, Ono H, Kawano T, Arai T, Kaneko K, Atsukawa M, Takeuchi K, Futagami S, Iwakiri K, Honda K. Risk stratification for malignant potential of intraductal papillary mucinous neoplasms using the apolipprotein-A2 isoforms blood test. Clinical and Translational Gastroenterology 2025. In press. DOI: 10.14309/ctg.0000000000000856.
25. Baba K, Suzuki N, Imamura CK, Booka E, Takahari D, Kawakami T, Kawakubo H, Kitagawa C, Kono Y, Ogura K, Kito Y, Saito K, Yamamoto S, Takeuchi H, Kudo T, Tsunoda T, Mizukami T, Yamaguchi T, Shoji H, Saito K, Tanoue K, Baba E, Nagashima K, Boku N. A phase I/II trial evaluating the safety of increased-dose S-1 with oxaliplatin and nivolumab in HER2-negative advanced gastric cancer. BMC Cancer 2025;25:675. DOI: 10.1186/s12885-025-14084-1.
26. Sado M, Nagashima K, Koreki A. Scoring system for the Japanese version of the ICECAP-A. Psychology Research and Behavior Management 2025;18:703–717. DOI: 10.2147/PRBM.S480328.
27. Hoshino K, Iwasawa S, Yoshioka N, Suzuki S, Hashimoto I, Ukita S, Toshima G, Nagashima K, Takebayashi T, Tsunoda M. Increased risk of proximal tubular dysfunction due to occupational cadmium exposure: a survival analysis study. Journal of Occupational Health 2025;67(1):uiaf016. DOI: 10.1093/joccuh/uiaf016.
28. Okui J*, Nagashima K*, Matsuda S*, Sato Y, Kawakubo H, Takeuchi M, Hirata K, Yamamoto S, Nomura M, Tsushima T, Takeuchi H, Kato K, Kitagawa Y. Investigating the synergistic effects of immunochemotherapy in esophageal squamous cell carcinoma. Esophagus 2025;22(2):188–197. DOI: 10.1007/s10388-025-01113-y. (*equally contributed)
29. Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Ishikawa K, Kaiho T, Asaumi N, Baba T, Yamamoto S, Yokote K, The COMET Trial investigators. Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: a randomised clinical trial. Diabetes, Obesity and Metabolism 2025;27(5):2473–2484. DOI: 10.1111/dom.16244.
30. Hirano H, Takahashi N, Amanuma Y, Suzuki N, Takahari D, Kawakami T, Kudo-Saito C, Nagashima K, Boku N, Kato K, Shoji H. Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE). BMC Cancer 2025;25(1):201. DOI: 10.1186/s12885-025-13591-5.
31. Watanabe T, Oka H, Nagashima K, Nishi H, Kumai Y, Iijima H, Okami K, Shimizu Y, Kano S, Ito K, Yamazaki T, Takahashi H, Oridate N, Yokota T, Koyama T, Kiyota N, Sato Y, Takahashi S, Kato K, Kadowaki S, Honma Y. Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study. The Oncologist 2025;30(3):oyaf018. DOI: 10.1093/oncolo/oyaf018.
32. Ishida N, Harada S, Toki R, Hirata A, Matsumoto M, Miyagawa N, Iida M, Edagawa S, Miyake A, Kuwabara K, Shibuki T, Kato S, Arakawa K, Kinoshita K, Sakurai-Yageta M, Tamiya G, Nagashima K, Muraoka H, Sato Y, Takebayashi T. Causal relationship between body mass index and insulin resistance: linear and nonlinear Mendelian randomization study in a Japanese population. Journal of Diabetes Investigation 2025;16(7):1305–1314. DOI: 10.1111/jdi.14377.
33. Yamada Y, Seto Y, Yoshikawa T, Takeuchi H, Kitagawa Y, Kodera Y, Doki Y, Yoshida K, Muro K, Kabeya Y, Kamada A, Nagashima K, Kumamaru H, Tachimori H, Sasako M, Katai H, Konno H, Kakeji Y. Postoperative adjuvant chemotherapy in patients with gastric cancer based on the Nationwide Gastric Cancer Registry in Japan. Global Health & Medicine 2025;7(1):13–27. DOI: 10.35772/ghm.2024.01080.
34. Yamaguchi R*, Oda T*, Nagashima K. Comparison of the diagnostic accuracy of shear wave elastography with transient elastography in adult nonalcoholic fatty liver disease: a systematic review and network meta-analysis of diagnostic test accuracy. Abdominal Radiology 2025;50(2):734–746. DOI: 10.1007/s00261-024-04546-8. (*equally contributed)
35. Inoue M, Ogasawara S, Kobayashi K, Okubo T, Itokawa N, Obu M, Fujimoto K, Unozawa H, Yumita S, Fujiwara K, Nakagawa M, Kanzaki H, Koroki K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakamoto S, Nagashima K, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Kato N. Assessment of macrovascular invasion in advanced hepatocellular carcinoma: clinical implications and treatment outcomes with systemic therapy. Liver Cancer 2025;14(1):8–18. DOI: 10.1159/000539380.
36. Shoji H, Kudo-Saito C, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Rika Kizawa R, Muro K, Aoki K, Boku N. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). Journal for ImmunoTherapy of Cancer 2024;12(11):e010174. DOI: 10.1136/jitc-2024-010174.
37. Matsuyama E, Miyata J, Terai H, Miyazaki N, Iwasaki T, Nagashima K, Watase M, Sunata K, Namkoong H, Asakura T, Masaki K, Chubachi S, Ohgino K, Kawada I, Minami K, Hagiwara R, Ueda S, Yoshiyama T, Kokuto H, Kusumoto T, Oashi A, Miyawaki M, Saito F, Tani T, Ishioka K, Takahashi S, Nakamura M, Ishii M, Sato Y, Fukunaga K. Chronic obstructive pulmonary disease, asthma, and mechanical ventilation are risk factors for dyspnea in patients with long COVID: a Japanese nationwide cohort study. Respiratory Investigation 2024;62(6):1094–1101. DOI: 10.1016/j.resinv.2024.09.009.
38. Takaoka H, Kawada I, Hiruma G, Nagashima K, Terai H, Ishida N, Namkoong H, Asakura T, Masaki K, Miyata J, Chubachi S, Ohgino K, Otsuka K, Miyao N, Odani T, Watase M, Baba R, Okamori S, Arai D, Nakachi I, Kuwahara N, Fujiwara A, Okada T, Ishiguro T, Isono T, Ishii M, Sato Y, Fukunaga K. Long COVID among the first three waves of COVID-19 in Japan: a multicentre cohort study. BMJ Open Respiratory Research 2024;11(1):e002137. DOI: 10.1136/bmjresp-2023-002137.
39. Yamaguchi T, Kumagai K, Yagi S, Nomura T, Nagashima K, Watanabe M, Makuuchi R, Kawakami K, Matsushima T, Kadowaki S, Haruta S, Cho H, Kakihara N, Otsuka S, Yamada T, Imai Y, Fukunaga H, Boku N. Efficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: A multicenter retrospective study. Scientific Reports 2024;14(1):21854. DOI: 10.1038/s41598-024-72423-x.
40. Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Morooka M, Ogushi M, Nagashima K, Sato Y, Kuriyama N, Kuwabara S. Multifocal motor neuropathy in Japan: A nationwide survey on prevalence, clinical profiles, and treatment. Muscle & Nerve 2024;70(5):1027–1033. DOI: 10.1002/mus.28251.
41. Katsumata Y, Muramoto Y, Ishida N, Takemura R, Nagashima K, Ikoma T, Kawamatsu N, Araki M, Goda A, Okawara H, Sawada T, Ichihara YK, Hattori O, Yamaoka K, Seki Y, Ryuzaki T, Ikura H, Nakashima D, Nagura T, Nakamura M, Sato K, Shiraishi Y. Sweat lactate sensor for detecting anaerobic threshold in heart failure: a prospective clinical trial (LacS-001). Scientific Reports 2024;14(1):18985. DOI: 10.1038/s41598-024-70001-9.
42. Fujita M, Nagashima K, Uno T, Hashimoto H, Suzuki K, Kasai T, Yamaguchi K, Onouchi Y, Sato D, Fujisawa T, Hata A. Impact of the COVID-19 pandemic on hypofractionated radiotherapy use for breast cancer in Japan: a nationwide study. Advances in Radiation Oncology 2024;9(8):101555. DOI: 10.1016/j.adro.2024.101555.
43. Hishikawa A, Nishimura ES, Yoshimoto N, Nakamichi R, Hama EY, Ito W, Maruki T, Nagashima K, Shimizu-Hirota R, Takaishi H, Itoh H, Hayashi K. Predicting exacerbation of renal function by DNA methylation clock and DNA damage of urinary shedding cells: a pilot study. Scientific Reports 2024;14(1):11530. DOI: 10.1038/s41598-024-62405-4.
44. Yoshitake M, Sugiyama A, Shimohata T, Araki N, Suzuki M, Shibuya K, Nagashima K, Hattori N, Kuwabara S. Delivering the diagnosis of multiple system atrophy: A multicenter survey on Japanese neurologists' perspectives. BMC Neurology 2024;24(1):137–146. DOI: 10.1186/s12883-024-03666-4.
45. Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M, Tsuruoka N, Kasai T, Hata A. Effectiveness of self-sampling human papillomavirus test on pre-cancer detection and screening uptake in Japan: The ACCESS randomized controlled trial. International Journal of Cancer 2024;155(5):905–915. DOI: 10.1002/ijc.34970.
46. Uchida S, Uno S, Kondo M, Uwamino Y, Namkoong H, Nishimura T, Misawa K, Kashimura S, Yamato K, Ishizaka T, Nagashima K, Kitagawa Y, Hasegawa N. Factors affecting motivation for receiving a booster dose of the COVID-19 vaccine among Japanese university students and staff: A cross-sectional questionnaire survey. Scientific Reports 2024;14(1):8009. DOI: 10.1038/s41598-024-58603-9.
47. Miyazaki N, Iwasaki T, Sakai H, Watanuki R, Tanizawa Y, Cai Z, Kawaguchi T, Tsurutani J, Nagashima K. Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis. Current Medical Research and Opinion 2024;40(5):827–837. DOI: 10.1080/03007995.2024.2332436.
48. Fujita M, Fujisawa T, Suzuki K, Nagashima K, Kasai T, Hashimoto H, Yamaguchi K, Onouchi Y, Sato D, Hata A. Impact of the coronavirus disease 2019 pandemic on primary and metastatic lung cancer treatments in Japan: A nationwide study using an interrupted time series analysis. Cancer Epidemiology 2024;90:102549. DOI: 10.1016/j.canep.2024.102549.
49. Fujita M, Yamaguchi K, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Onouchi Y, Sato D, Fujisawa T, Hata A. Impact of the COVID-19 pandemic on gastric surgery in Japan: A nationwide study using interrupted time-series analyses. Journal of Gastroenterology and Hepatology 2024;39(7):1277–1284. DOI: 10.1111/jgh.16533.
50. Okada M, Ishida N, Kanzaki S, Kawada I, Nagashima K, Terai H, Hiruma G, Namkoong H, Asakura T, Masaki K, Ohgino K, Miyata J, Chubachi S, Kodama N, Maeda S, Sakamoto S, Okamoto M, Nagasaki Y, Umeda A, Miyagawa K, Shimada H, Minami K, Hagiwara R, Ishii M, Sato Y, Fukunaga K. Upper respiratory symptoms as long COVID revealed through a cohort study of patients with COVID-19. OTO Open 2024;8(1):e120. DOI: 10.1002/oto2.120.
51. Tsutsui K, Ukita S, Kondo M, Toshima G, Miyazaki N, Nagashima K, Ohmura M, Tsuchihashi S, Tsuji Y, Katoh M, Aida N, Kobayashi Y, Ohtsu Y, Fujita Y, Tanaka S, Watanabe H, Naruse Y, Iizuka I, Kato H, Mashimo Y, Senbonmatsu T. Synergistic effect of motivation for the elderly and support for going out II; measures to induce elderly men to go out. Geriatrics 2024;9(1):21. DOI: 10.3390/geriatrics9010021.
52. Okui J*, Nagashima K*, Matsuda S*, Sato Y, Okamura A, Kawakubo H, Muto M, Kakeji Y, Kono K, Takeuchi H, Watanabe M, Doki Y, Bamba T, Fukuda T, Fujiwara H, Sato S, Noma K, Miyata H, Fujita T, Kitagawa Y. Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. British Journal of Surgery 2024;111(2):znae038. DOI: 10.1093/bjs/znae038. (*equally contributed)
53. Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Marie M, Ogushi M, Nagashima K, Sato Y, Kuriyama N, Kuwabara S. Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients. European Journal of Neurology 2024;31(5):e16249. DOI: 10.1111/ene.16249.
54. Yamada Y, Nagashima K, Azuma M, Masutani M, Ichikawa H, Iwasa S, Takahashi N, Hirano H, Kanato K, Machida N, Kinoshita T, Hata H, Kawakami H, Takahari D, Boku N, Kurokawa Y, Terashima M, Yoshikawa T, Sekine S, Hiraoka N. Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer. BJC Reports 2024; 2: 18. DOI: 10.1038/s44276-024-00046-w.
55. Kashiro A, Kobayashi M, Oh T, Miyamoto M, Atsumi J, Nagashima K, Takeuchi K, Nara S, Hijioka S, Morizane C, Kikuchi S, Kato S, Kato K, Ochiai H, Obata D, Shizume Y, Konishi H, Nomura Y, Matsuyama K, Xie C, Wong C, Huang Y, Jung G, Srivastava S, Kutsumi H, Honda K. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer. Journal of Gastroenterology 2024; 59(3): 263–278. DOI: 10.1007/s00535-023-02072-w.
56. Aotsuka Y, Misawa S, Suichi T, Shibuya K, Nakamura K, Kano H, Otani R, Morooka M, Ogushi M, Nagashima K, Sato Y, Kuriyama N, Kuwabara S. Prevalence, clinical profiles, and prognosis of CIDP in Japanese nationwide survey: analyses of 1257 diagnosis-confirmed patients. Neurology 2024;102(6):e209130. DOI: 10.1212/WNL.0000000000209130.
57. Kishimoto T, Kinoshita S, Kitazawa M, Hishimoto A, Asami T, Suda A, Bun S, Kikuchi T, Sado M, Takamiya A, Mimura M, Sato Y, Takemura R, Nagashima K, Nakamae T, Abe Y, Kanazawa T, Kawabata Y, Tomita H, Abe K, Hongo S, Kimura H, Sato A, Kida H, Sakuma K, Funayama M, Sugiyama N, Hino K, Amagai T, Takamiya M, Kodama H, Goto K, Fujiwara S, Kaiya H, Nagao K, on behalf of the J-PROTECT collaborators. Live two-way video versus face-to-face treatment for depression, anxiety, and obsessive-compulsive disorder: A 24-week randomized controlled trial. Psychiatry and Clinical Neurosciences 2024; 78(4): 220–228. DOI: 10.1111/pcn.13618.
58. Shimozaki K, Nakayama I, Takahari D, Nagashima K, Yoshino K, Fukuda K, Fukuoka S, Osumi H, Ogura M, Wakatsuki T, Ooki A, Shinozaki E, Chin K, Yamaguchi K. Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: a single-institution retrospective study. Journal of Gastric Cancer 2023;23(4):e41. DOI: 10.5230/jgc.2023.23.e41.
59. Nomura K, Kitagawa K, Tsuji M, Iida M, Aoki M, Miyauchi K, Hirayama J, Nagashima K, Takebayashi T, Tsutsumi A. The quantity and quality of scientific evidence about the health of working women in occupational health of Japan: A scoping review. Journal of Occupational Health 2023;65(1):e12427. DOI: 10.1002/1348-9585.12427.
60. Terai H, Ishii M, Takemura R, Namkoong H, Shimamoto K, Masaki K, Tanosaki T, Chubachi S, Matsuyama E, Hayashi R, Shimada T, Shigematsu L, Ito F, Kaji M, Takaoka H, Kurihara M, Nakagawara K, Tomiyasu S, Sasahara K, Saito A, Otake S, Azegawa S, Okada M, Fukushima T, Morita A, Tanaka H, Sunata K, Asaoka M, Nishie M, Shinozaki T, Ebisudani T, Akiyama Y, Mitsuishi A, Nakayama S, Ogawa T, Sakurai K, Irie M, Yagi K, Ohgino K, Miyata J, Kabata H, Ikemura S, Kamata H, Yasuda H, Kawada I, Kimura R, Kondo M, Iwasaki T, Ishida N, Hiruma G, Miyazaki N, Ishibashi Y, Harada S, Fujita T, Ito D, Bun S, Tabuchi H, Kanzaki S, Shimizu E, Fukuda K, Yamagami J, Kobayashi K, Hirano T, Inoue T, Haraguchi M, Kagyo J, Shiomi T, Lee H, Sugihara K, Omori N, Sayama K, Otsuka K, Miyao N, Odani T, Watase M, Mochimaru T, Satomi R, Oyamada Y, Masuzawa K, Asakura T, Nakayama S, Suzuki Y, Baba R, Okamori S, Arai D, Nakachi I, Kuwahara N, Fujiwara A, Okada T, Ishiguro T, Isono T, Mashimo S, Makino Y, Kaido T, Minematsu N, Ueda S, Minami K, Hagiwara R, Manabe T, Fukui T, Funatsu Y, Koh H, Yoshiyama T, Kokuto H, Kusumoto T, Oashi A, Miyawaki M, Saito F, Tani T, Ishioka K, Takahashi S, Nakamura M, Harada N, Sasano H, Goto A, Kusaka Y, Ohba T, Nakano Y, Nishio K, Nakajima Y, Suzuki S, Yoshida S, Tateno H, Kodama N, Maeda S, Sakamoto S, Okamoto M, Nagasaki Y, Umeda A, Miyagawa K, Shimada H, Hagimura K, Nagashima K, Sato T, Sato Y, Hasegawa N, Takebayashi T, Nakahara J, Mimura M, Ogawa K, Shimmura S, Negishi K, Tsubota K, Amagai M, Goto R, Ibuka Y, Kitagawa Y, Kanai T, Fukunaga K. Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study. Respiratory Investigation 2023; 61(6): 802–814. DOI: 10.1016/j.resinv.2023.08.008. [Preprint].
61. Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Machida E, Kohno T, Yatabe Y, Kanemitsu Y, Hamamoto R, Takashima A, Shiraishi K, Sekine S. A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer. British Journal of Cancer 2023;129(7):1176–1183. DOI: 10.1038/s41416-023-02382-z.
62. Takahashi N, Hara H, Nagashima K, Hirata K, Masuishi T, Matsumoto T, Kawakami H, Yamazaki K, Hironaka S, Boku N, Muro K. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G). BMC Cancer 2023; 23(1): 726. DOI: 10.1186/s12885-023-11199-1.
63. Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M, Tsuruoka N, Kasai T, Hata A. Acceptability of self-sampling human papillomavirus test for cervical cancer screening in Japan: A questionnaire survey in the ACCESS trial. PLoS ONE 2023; 18(6): e0286909. DOI: 10.1371/journal.pone.0286909.
64. Fujita M, Yamaguchi K, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Onouchi Y, Sato D, Fujisawa T, Hata A. Changes in colorectal cancer treatment during the COVID-19 pandemic in Japan: interrupted time-series analysis using the National Database of Japan. Cancer Epidemiology 2023; 85: 102391. DOI: 10.1016/j.canep.2023.102391.
65. Fujita M, Hashimoto H, Nagashima K, Suzuki K, Kasai T, Yamaguchi K, Onouchi Y, Sato D, Fujisawa T, Hata A. Impact of coronavirus disease 2019 pandemic on breast cancer surgery using the National Database of Japan. Scientific Reports 2023; 13(1): 4977. DOI: 10.1038/s41598-023-32317-w.
66. Takahashi R, Uchiyama K, Washida N, Shibagaki K, Yanai A, Nakayama T, Nagashima K, Sato Y, Kanda T, Itoh H. Mean annual intradialytic blood pressure decline and cardiovascular events in Japanese patients on maintenance hemodialysis. Hypertension Research 2023; 46(6): 1536–1546. DOI: 10.1038/s41440-023-01228-8.
67. Uwamino Y*, Nagashima K*, Yoshifuji A, Suga S, Nagao M, Fujisawa T, Ryuzaki M, Takemoto Y, Namkoong H, Wakui M, Matsushita H, Hasegawa N, Sato Y, Murata M. Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination. npj Vaccines 2023; 8(1): 33. DOI: 10.1038/s41541-023-00626-w. (*equally contributed)
68. Kadono T, Iwasa S, Nagashima K, Oshima K, Yamamoto S, Hirano H, Okita N, Shoji H, Honma Y, Takashima A, Kato K, Ushijima T, Boku N. Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. Cancer Medicine 2023; 12(8): 9322–9331. DOI: 10.1002/cam4.5689.
69. Nakamura M, Ogawa R, Fujimori J, Uzawa A, Sato Y, Nagashima K, Kuriyama N, Kuwabara S, Nakashima I. Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Multiple Sclerosis Journal 2023;29(4–5): 530–539. DOI: 10.1177/13524585231156736.
70. Matsumura T, Ebigbo A, Römmele C, Ikematsu H, Ishigami H, Suzuki T, Harada H, Yada T, Takatori Y, Takeuchi M, Okimoto K, Akizue N, Maruoka D, Kitagawa Y, Minamide T, Iwaki T, Amano Y, Matsusaka K, Nagashima K, Maehata T, Yahagi N, Messmann H, Kato N. Diagnostic value of adding magnifying chromoendoscopy to magnifying narrow-band imaging endoscopy for colorectal polyps. Clinical Gastroenterology and Hepatology 2023; 21(10): 2551–2559.e2. DOI: 10.1016/j.cgh.2023.01.028.
71. Kubo A, Masugi Y, Hase T, Nagashima K, Kawai Y, Takizawa M, Hishiki T, Shiota M, Wakui M, Kitagawa Y, Kabe Y, Sakamoto M, Yachie A, Hayashida T, Suematsu M. Polysulfide serves as a hallmark of desmoplastic reaction to differentially diagnose ductal carcinoma in situ and invasive breast cancer by SERS imaging. Antioxidants 2023; 12(2): 240. DOI: 10.3390/antiox12020240.
72. Kojima D, Washida N, Uchiyama K, Hama EY, Nagasaka T, Kusahana E, Nakayama T, Nagashima K, Sato Y, Morimoto K, Kanda T, Itoh H. The body mass index change is associated with death or hemodialysis transfer in Japanese patients initiating peritoneal dialysis. Renal Failure 2023; 45(1):2163904. DOI: 10.1080/0886022X.2022.2163904.
73. Yamaguchi Y, Takashima A, Nagashima K, Kumagai K, Yamada T, Terashima M, Yabusaki H, Nishikawa K, Tanabe K, Yunome G, Kawachi Y, Yamada T, Fukagawa T, Kinoshita T, Watanabe M, Ishiyama K, Inoue K, Boku N. Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study. Gastric Cancer 2023;26(2):307–316. DOI: 10.1007/s10120-023-01363-8.
74. Fujita M, Nagashima K, Suzuki K, Kasai T, Hashimoto H, Yamaguchi K, Onouchi Y, Sato D, Fujisawa T, Hata A. Changes in the number of cancer diagnosis practices due to the COVID-19 pandemic: interrupted time-series analysis using the National Database of Japan. Journal of Cancer Research and Clinical Oncology 2023;149(9):6023–6033. DOI: 10.1007/s00432-022-04557-2.
75. Numasaki M, Ito K, Takagi K, Nagashima K, Notsuda H, Ogino H, Ando R, Tomioka Y, Suzuki T, Okada Y, Nishioka Y, Unno M. Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8. Cellular Immunology 2023;383:104652. DOI: 10.1016/j.cellimm.2022.104652.
76. Imamura S, Inagaki T, Abe M, Terada J, Kawasaki T, Nagashima K, Tatsumi K, Suzuki T. Impaired dynamic response of oxygen saturation during the 6-min walk test is associated with mortality in chronic fibrosing interstitial pneumonia. Respiratory Care 2023;68(3):356–365. DOI: 10.4187/respcare.10231
77. Aoki M, Kadowaki S, Takahashi N, Suzuki T, Oshima K, Ando T, Yamamoto Y, Kawakami K, Kito Y, Matsumoto T, Shimozaki K, Miyazaki Y, Yamaguchi T, Nagase M, Tamura T, Amanuma Y, Esaki T, Miura Y, Akiyoshi K, Baba E, Makiyama A, Negoro Y, Nakashima K, Sugimoto N, Nagashima K, Shoji H, Boku N. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan. Gastric Cancer 2023;26(1):132–144. DOI: 10.1007/s10120-022-01349-y.
78. Tamura NT, Shikimoto R, Nagashima K, Sato Y, Nakagawa A, Irie S, Iwashita S, Mimura M, Fujisawa D. Group multi-component programme based on cognitive behavioural therapy and positive psychology for family caregivers of people with dementia: a randomised controlled study (3C study). Psychogeriatrics 2023;23(1):141–156. DOI: 10.1111/psyg.12919.
79. Ota Y, Nomura K, Fujita N, Suzuki T, Kamatsuka M, Sakata N, Nagashima K, Hirayama J, Fujita N, Shiga K, Oyama N, Terada Y. Influence of LINE-assisted provision of information about human papillomavirus and cervical cancer prevention on HPV vaccine intention: A randomized controlled trial. Vaccines 2022;10(12):2005. DOI: 10.3390/vaccines10122005.
80. Yamada Y, Kobayashi H, Nagashima K, Sugihara K. Real impact of oxaliplatin in adjuvant chemotherapy for patients with stage III colon cancer based on the Multi-Institutional Registry of Large Bowel Cancer in Japan. Global Health & Medicine 2022;4(5):259–267. DOI: 10.35772/ghm.2022.01048.
81. Suzuki T, Ota Y, Sakata N, Fujita N, Kamatsuka M, Nagashima K, Hirayama J, Terada Y, Nomura K. HPV vaccine intention among university students during suspension of active recommendation in Japan. Human Vaccines & Immunotherapeutics 2022;18(6):2116900. DOI: 10.1080/21645515.2022.2116900.
82. Fujita M, Nagashima K, Shimazu M, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Hanaoka H, Shozu M, Tsuruoka N, Kasai T, Hata A. Implementation of a self-sampling HPV test for non-responders to cervical cancer screening in Japan: secondary analysis of the ACCESS trial. Scientific Reports 2022;12(1):14531. DOI: 10.1038/s41598-022-18800-w.
83. Hirata K, Sato T, Nakamura M, Kato K, Hirano H, Kumekawa Y, Hino K, Kawakami K, Kito Y, Matsumoto T, Kawakami T, Komoda M, Nagashima K, Sato Y, Yamazaki K, Hironaka S, Takaishi H, Hamamoto Y, Muro K. WJOG13219G: the efficacy and safety of FOLFOXIRI or doublet plus anti-VEGF therapy in previously untreated BRAF^V600E mutant metastatic colorectal cancer: a multi-institutional registry-based study (BRACELET study). Clinical Colorectal Cancer 2022;21(4):339–346. DOI: 10.1016/j.clcc.2022.08.002.
84. Eriguchi T, Takeda A, Nemoto T, Tsurugai Y, Sanuki N, Tateishi Y, Kibe Y, Akiba T, Inoue M, Nagashima K, Horita N. Relationship between dose prescription methods and local control rate in stereotactic body radiotherapy for early-stage non-small cell lung cancer: systematic review and meta-analysis. Cancers 2022;14(15):3815. DOI: 10.3390/cancers14153815.
85. Mashimo Y, Tsuchihashi S, Tsutsui K, Arai T, Tsuji Y, Numai T, Kameda K, Nishizawa K, Kobati M, Tanaka S, Watanabe H, Naruse Y, Ohmura M, Ishida N, Iwasaki T, Hiruma G, Miyazaki N, Takemura R, Nagashima K, Sato Y, Ohtsu Y, Nakano T, Aida N, Iizuka I, Kato H, Kobayashi Y, Senbonmatsu T. Synergistic effect of motivation for the elderly and support for going out. Journal of Personalized Medicine 2022;12(8):1257. DOI: 10.3390/jpm12081257.
86. Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Saruta M, Otsu S, Shinozaki K, Fujiwara T, Tamura T, Baba E, Shiozawa M, Denda T, Ueno H, Nagashima K, Shimada Y. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. International Journal of Clinical Oncology 2022;27(9):1450–1458. DOI: 10.1007/s10147-022-02208-7.
87. Hashimoto T, Takayanagi D, Yonemaru J, Naka T, Nagashima K, Yatabe Y, Shida D, Hamamoto R, Kleeman SO, Leedham SJ, Maughan T, Takashima A, Shiraishi K, Sekine S. Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer. British Journal of Cancer 2022;127(6):1043–1050. DOI: 10.1038/s41416-022-01880-w.
88. Watanabe K, Shibuya K, Misawa S, Nagashima K, Suzuki Y-i, Suichi T, Kojima Y, Nakamura K, Kano H, Prado M, Uzawaa A, Kuwabara S. Impaired neuromuscular transmission in facial muscles of amyotrophic lateral sclerosis: A single-fiber electromyography study. Neurology and Clinical Neuroscience 2022;10(2):78–82. DOI: 10.1111/ncn3.12580.
89. Fujita M, Shimazu M, Nagashima K, Suzuki M, Tauchi I, Sakuma M, Yamamoto S, Shozu M, Hanaoka H, Tsuruoka N, Kasai T, Hata A. Study protocol of the ACCESS trial: A randomized trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection. BMJ Open 2022;12(2):e049803. DOI: 10.1136/bmjopen-2021-049803.
90. Noro R, Honda K, Nagashima K, Motoi N, Kunugi S, Matsubayashi J, Takeuchi S, Shiraishi H, Okano T, Kashiro A, Meng X, Yoshida Y, Watanabe S-i, Usuda J, Inoue T, Wilber H, Ikeda N, Seike M, Gemma A, Kubota K. Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas. Cancer Science 2022;113(3):1002–1009. DOI: 10.1111/cas.15228.
91. Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Evolution of survival impact of molecular target agents in patients with advanced hepatocellular carcinoma. Liver Cancer 2022;11(1):48–60. DOI: 10.1159/000519868.
92. Hasegawa T, Seo T, Kubota Y, Sudo T, Yokota K, Miyazaki N, Muranaka A, Hirano S, Yamauchi A, Nagashima K, Iyo M, Sakai I. Reliability and validity of the Japanese version of the 4A's Test for delirium screening in the elderly patient. Asian Journal of Psychiatry 2022;67:102918. DOI: 10.1016/j.ajp.2021.102918.
93. Felix K*, Honda K*, Nagashima K, Kashiro A, Takeuchi K, Kobayashi T, Hinterkopf S, Gaida MM, Dang H, Brindl N, Kaiser J, Büchler MW, Strobel O. Non-invasive risk stratification of IPMN with malignant potential by serum apolipoprotein-A2-isoforms. International Journal of Cancer 2022;150(5):881–894. DOI: 10.1002/ijc.33875. (*equally contributed)
94. Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y, Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N. Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. BMC Cancer 2021;21(1):1159. DOI: 10.1186/s12885-021-08890-6.
95. Shoji H, Takahari D, Hara H, Nagashima K, Adachi J, Boku N. A phase I study of pevonedistat plus CapeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811). Future Science OA 2021;7(7):FSO721. DOI: 10.2144/fsoa-2021-0023.
96. Honda K, Hishiki T, Yamamoto S, Yamamoto T, Miura N, Kubo A, Itoh M, Chen W-Y, Takano M, Yoshikawa T, Kasamatsu T, Sonoda S, Yoshizawa H, Nakamura S, Itai Y, Shiota M, Koike D, Naya M, Hayakawa N, Naito Y, Matsuura T, Iwaisako K, Masui T, Uemoto S, Nagashima K, Hashimoto Y, Sakuma T, Matsubara O, Huang W, Ida T, Akaike T, Masugi Y, Sakamoto M, Kato T, Ino Y, Yoshida H, Tsuda H, Hiraoka N, Kabe Y, Suematsu M. On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biology 2021;41:101926. DOI: 10.1016/j.redox.2021.101926.
97. Iwase M, Matsuura Y, Kuniyoshi K, Suzuki T, Nagashima K, Ohtori S. Biomechanical evaluation of opponenplasty for low median palsy: a cadaver study. Journal of Hand Surgery Global Online 2021;3(2):74–80. DOI: 10.1016/j.jhsg.2020.11.002.
98. Yamaguchi T, Takashima A, Nagashima K, Terashima M, Aizawa M, Ohashi M, Tanaka R, Yamada T, Kinoshita T, Inada T, Ishiyama K, Ema A, Yuasa Y, Haruta S, Kakihara N, Nishikawa K, Yunome G, Satoh T, Fukagawa T, Katai H, Boku N. Impact of preoperative chemotherapy as initial treatment for advanced gastric cancer with peritoneal metastasis limited to positive peritoneal lavage cytology (CY1) or localized peritoneal metastasis (P1a): A multi-institutional retrospective study. Gastric Cancer 2021;24(3):701–709. DOI: 10.1007/s10120-020-01137-6.
99. Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, on behalf of the PRIME-V study group. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Sub-analysis of a prospective, randomized, controlled study (PRIME-V study). Journal of Diabetes Investigation 2021;12(2):200–206. DOI: 10.1111/jdi.13340.
100. Sato Y, Kobayashi T, Nishiumi S, Okada A, Fujita T, Sanuki T, Kobayashi M, Asahara M, Adachi M, Sakai A, Shiomi H, Masuda A, Yoshida M, Takeuchi K, Kodama Y, Kutsumi H, Nagashima K, Honda K. Prospective study using plasma apolipoprotein A2-isoforms to screen for high-risk status of pancreatic cancer. Cancers 2020;12(9):2625. DOI: 10.3390/cancers12092625.
101. Nomura K, Minamizono S, Nagashima K, Ono M, Kitano N. Maternal body mass index and breastfeeding non-initiation and cessation: a quantitative review of the literature. Nutrients 2020;12(9):2684. DOI: 10.3390/nu12092684.
102. Imamura S, Inagaki T, Terada J, Nagashima K, Katsura H, Tatsumi K. Long-term efficacy of pulmonary rehabilitation with home-based or low frequent maintenance programs in patients with chronic obstructive pulmonary disease: a meta-analysis. Annals of Palliative Medicine 2020;9(5):2606–2615. DOI: 10.21037/apm-19-581.
103. Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Asaumi N, Arai M, Shimada F, Tachibana K, Watanabe Y, Ishikawa K, Hoshino A, Yamamoto K, Kubota-Taniai M, Mayama T, Yamamoto S, Yokote K. Safety and efficacy of ranibizumab and luseogliflozin combination therapy in diabetic macular edema patients: protocol for a multicenter, randomized controlled, open-label trial. Diabetes Therapy 2020;11(8):1891–1905. DOI: 10.1007/s13300-020-00854-6.
104. Ueshima K, Ogasawara S, Ikeda M, Yasui Y, Terashima T, Yamashita T, Obi S, Sato S, Aikata H, Ohmura T, Kuroda H, Ohki T, Nagashima K, Ooka Y, Takita M, Kurosaki M, Chayama K, Kaneko S, Izumi N, Kato N, Kudo M, Omata M. Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma. Liver Cancer 2020;9(5):583–595. DOI: 10.1159/000508724.
105. Yamamoto S, Kato K, Daiko H, Kojima T, Hara H, Abe T, Tsubosa Y, Nagashima K, Aoki K, Mizoguchi Y, Kitano S, Yachida S, Shiba S, Kitagawa Y. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncology 2020;16(19):1351–1357. DOI: 10.2217/fon-2020-0189.
106. Nagata Y, Kato K, Miyamoto T, Hirano H, Shoji H, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Matsushita H, Nagashima K, Saruta M, Boku N. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy. Supportive Care in Cancer 2020;28(12):5861–5869. 10.1007/s00520-020-05401-4.
107. Katsumata Y, Terada J, Matsumura T, Koshikawa K, Sakao S, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda H, Nagashima K, Kobayashi Y, Kobayashi E, Iwadate Y, Zhang X-M, Hiwasa T, Tatsumi K. Circulating anti-sorting nexins 16 antibodies as an emerging biomarker of coronary artery disease in patients with obstructive sleep apnea. Diagnostics 2020;10(2):71. DOI: 10.3390/diagnostics10020071.
108. Suichi T, Misawa S, Nagashima K, Sato Y, Iwai Y, Katayama K, Sekiguchi Y, Shibuya K, Amino H, Suzuki Y-i, Tsuneyama A, Nakamura K, Kuwabara S. Lenalidomide treatment for thalidomide-refractory POEMS syndrome: A prospective single-arm clinical trial. Internal Medicine 2020;59(9):1149–1153. DOI: 10.2169/internalmedicine.3800-19.
109. Ishikawa M, Iwasa S, Aoki M, Imazeki H, Hirano H, Shoji H, Honma Y, Okita N, Nagashima K, Takashima A, Kato K, Saruta M, Boku N. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. Investigational New Drugs 2020;38(2):533–540. DOI: 10.1007/s10637-019-00822-3.
110. Iwase T, Sangai T, Fujimoto H, Sawabe Y, Matsushita K, Nagashima K, Sato Y, Nakagawa A, Masuda T, Nagashima T, Ohtsuka M. Quality and quantity of visceral fat tissue are associated with insulin resistance and survival outcomes after chemotherapy in patients with breast cancer. Breast Cancer Research and Treatment 2020;179(2):435–443. DOI: 10.1007/s10549-019-05467-7.
111. Satomi NT, Honma Y, Nagashima K, Umezawa R, Ito Y, Hirano H, Shoji H, Takashima A, Iwasa S, Kato K, Hamaguchi T, Itami J, Boku N. Risk factors of severe benign cicatricial stricture after definitive chemoradiation for localized T3 esophageal carcinoma. Anticancer Research 2020;40(2):1071–1077. DOI: 10.21873/anticanres.14045.
112. Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, Inaba K, Ito Y, Itami J, Kanamori J, Oguma J, Daiko H. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. Cancer Medicine 2020;9(2):595–604. DOI: 10.1002/cam4.2708.
113. Fujita M, Nagashima K, Takahashi S, Suzuki K, Fujisawa T, Hata A. Hand-held flow meter improves COPD detectability regardless of using a conventional questionnaire: a split-sample validation study. Respirology 2020;25(2):191–197. DOI: 10.1111/resp.13602.
114. Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, Tashiro K, Yamada T, Kinoshita T, Hata H, Kawachi Y, Kawabata R, Tsuji T, Hihara J, Sakamoto T, Fukagawa T, Katai H, Higuchi K, Boku N. Efficacy of post-operative chemotherapy after resection leaving no macroscopically visible disease of gastric cancer with peritoneal lavage cytology positive (CY1) or localized peritoneum metastasis (P1a): a multicenter retrospective study. Annals of Surgical Oncology 2020;27(1):284–292. DOI: 10.1245/s10434-019-07697-x.
115. Nomura K, Nagashima K, Suzuki T, Itoh H. Application of Japanese guidelines for gestational weight gain to multiple pregnancy outcomes and its optimal range in 101,336 Japanese women. Scientific Reports 2019;9(1):17310. DOI: 10.1038/s41598-019-53809-8.
116. Masuda K, Shoji H, Nagashima K, Yamamoto S, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer 2019;19(1):974. DOI: 10.1186/s12885-019-6150-y.
117. Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T. Changes in conditional net survival and dynamic prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy. Cancer Medicine 2019;8(15):6566–6577. DOI: 10.1002/cam4.2502.
118. Narita S, Nomura K, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nagashima K, Habuchi T. Prognostic significance of early changes in serum biomarker levels in patients with newly diagnosed metastatic prostate cancer. Scientific Reports 2019;9(1):12071. DOI: 10.1038/s41598-019-48600-8.
119. Monma S, Kato K, Shouji H, Okita N, Takashima A, Honma Y, Iwasa S, Hamaguchi T, Yamada Y, Shimada Y, Boku N, Nagashima K, Ito Y, Itami J. Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer. Esophagus 2019;16(4):402–407. DOI: 10.1007/s10388-019-00680-1.
120. Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K, On behalf of the PRIME-V study group. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised controlled study (PRIME-V study). Diabetes, Obesity and Metabolism 2019;21(8):1990–1995. DOI: 10.1111/dom.13750.
121. Fujita M, Nagashima K, Takahashi S, Hata A. Inequality within a community at the neighborhood level and the incidence of mood disorders in Japan: a multilevel analysis. Social Psychiatry and Psychiatric Epidemiology 2019;54(9):1125–1131. DOI: 10.1007/s00127-019-01687-w.
122. Aoki M, Shoji H, Nagashima K, Imazeki H, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Higuchi K, Boku N. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. ESMO Open 2019;4:e000488. DOI: 10.1136/esmoopen-2019-000488.
123. Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S, Tatsumi K. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Drug Design, Development and Therapy 2019;13:809–816. DOI: 10.2147/DDDT.S197237.
124. Hiramoto S, Tamaki T, Nagashima K, Hori T, Kikuchi A, Yoshioka A, Inoue A. Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer. International Journal of Clinical Oncology 2019;24(4):454–459. DOI: 10.1007/s10147-018-1363-7.
125. Hashimoto J, Kato K, Ito Y, Kojima T, Akimoto T, Daiko H, Hamamoto Y, Matsushita H, Katano S, Hara H, Tanaka Y, Saito Y, Nagashima K, Igaki H. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma. International Journal of Clinical Oncology 2019;24(1):60–67. DOI: 10.1007/s10147-018-1336-x.
126. Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Shimada Y, Yamada Y. Imaging peritoneal metastasis of gastric cancer with ¹⁸F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. British Journal of Radiology 2018;91(1089):20180259. DOI: 10.1259/bjr.20180259.
127. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Medical costs attributable to overweight and obesity in Japanese individuals. Obesity Research & Clinical Practice 2018;12(5):479–484. DOI: 10.1016/j.orcp.2018.06.002.
128. Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Nagashima K, Hanaoka H, Kobayashi Y. Intravenous nicorandil versus adenosine for fractional flow reserve measurement: A crossover, randomized study. Heart and Vessels 2018;33(12):1570–1575. DOI: 10.1007/s00380-018-1197-2.
129. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kanouchi T, Kohara N, Kawamoto M, Ishii J, Kuwahara M, Suzuki H, Hirata K, Kokubun N, Masuda R, Kaneko J, Yabe I, Sasaki H, Kaida K-i, Takazaki H, Suzuki N, Suzuki S, Nodera H, Matsui N, Tsuji S, Koike H, Yamasaki R, Kusunoki S, for the Japanese Eculizumab Trial for GBS (JET-GBS) Study Group. Safety and efficacy of eculizumab in Guillain–Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. The Lancet Neurology 2018;17(6):519–529. DOI: 10.1016/S1474-4422(18)30114-5.
130. Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizogami M, Hata A. Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan. Journal of Viral Hepatitis 2018;25(11):1312–1320. DOI: 10.1111/jvh.12933.
131. Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, Sakao S, Nagashima K, Ozaki T, Kobayashi Y, Hiwasa T, Tatsumi K. Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): a potential biomarker for coronary artery disease in patients with obstructive sleep apnea. PLoS ONE 2018;13(3):e0195015. DOI: 10.1371/journal.pone.0195015.
132. Yamaguchi T, Kato K, Nagashima K, Iwasa S, Honma Y, Takashima A, Hamaguchi T, Ito Y, Itami J, Boku N, Higuchi K. Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma. International Journal of Clinical Oncology 2018;23(4):652–658. DOI: 10.1007/s10147-018-1258-7.
133. Watanabe K, Hirano S, Kojima K, Nagashima K, Mukai H, Sato T, Takemoto M, Matsumoto K, Iimori T, Isose S, Omori S, Shibuya K, Sekiguchi Y, Beppu M, Amino H, Suichi T, Yokote K, Uno T, Kuwabara S, Misawa S. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. Journal of Neurology, Neurosurgery, and Psychiatry 2018;89(10):1082–1087. DOI: 10.1136/jnnp-2017-316601.
134. Kotooka N, Kitakaze M, Nagashima K, Asaka M, Kinugasa Y, Nochioka K, Mizuno A, Nagatomo D, Mine D, Yamada Y, Kuratomi A, Okada N, Fujimatsu D, Kuwahata S, Toyoda S, Hirotani S-i, Komori T, Eguchi K, Kario K, Inomata T, Sugi K, Yamamoto K, Tsutsui H, Masuyama T, Shimokawa H, Momomura S-i, Seino Y, Sato Y, Inoue T, Node K, On behalf of the HOMES-HF study investigators. The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF). Heart and Vessels 2018;33(8):866–876. DOI: 10.1007/s00380-018-1133-5.
135. Inagaki T, Terada J, Yahaba M, Kawata N, Jujo T, Nagashima K, Sakao S, Tanabe N, Tatsumi K. Heart rate and oxygen saturation change patterns during 6-min walk test in subjects with chronic thromboembolic pulmonary hypertension. Respiratory Care 2018;63(5):573–583. DOI: 10.4187/respcare.05788.
136. Sasaki Y, Iwasa S, Okazaki S, Goto M, Kojima Y, Naganuma A, Nagashima K, Nagai Y, Hirano H, Honma Y, Takashima A, Kato K, Hamaguchi T. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer. Gastric Cancer 2018;21(3):439–445. DOI: 10.1007/s10120-017-0753-2.
137. Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. International Journal of Clinical Oncology 2018;23(2):382–388. DOI: 10.1007/s10147-017-1200-4.
138. Kinoshita T, Yahaba M, Terada J, Matsumura T, Sakurai Y, Sakao S, Nagashima K, Tatsumi K. Impact of arterial stiffness on WatchPAT variables in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine 2018;14(3):319–325. DOI: 10.5664/jcsm.6970.
139. Korematsu S, Nagashima K, Sato Y, Nagao M, Hasegawa S, Nakamura H, Sugiura S, Miura K, Okada K, Fujisawa T. "Spike" in acute asthma exacerbations during enterovirus D68 epidemic in Japan: A nation-wide survey. Allergology International 2018;67(1):55–60. DOI: 10.1016/j.alit.2017.04.003.
140. Iizumi S, Takashima A, Narita Y, Tajika M, Muro K, Kawai S, Yasui H, Matsushima T, Takahari D, Nagashima K, Boku N. Efficacy and safety of taxane-monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. Cancer Chemotherapy and Pharmacology 2017;80(3):575–582. DOI: 10.1007/s00280-017-3397-3.
141. Shiraishi H, Fujiwara Y, Kakuya T, Tsuta K, Motoi N, Miura N, Watabe Y, Watanabe S-i, Noro R, Nagashima K, Huang W, Yamada T, Asamura H, Ohe Y, Honda K. Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomarkers in Medicine 2017;11(9):721–731. DOI: 10.2217/bmm-2017-0150.
142. Honma Y, Hokamura N, Nagashima K, Sudo K, Shoji H, Iwasa S, Takashima A, Kato K, Hamaguchi T, Boku N, Ito Y, Itami J, Koyanagi K, Igaki H, Tachimori Y. Clinical outcomes of resectable esophageal cancer with supraclavicular lymph node metastases treated with curative intent. Anticancer Research 2017;37(7):3741–3749. DOI: 10.21873/anticanres.11748.
143. Nishide A, Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income-related inequalities in access to dental care services in Japan. International Journal of Environmental Research and Public Health 2017;14(5):524. DOI: 10.3390/ijerph14050524.
144. Shoji H, Heike Y, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Hamaguchi T. The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy. Oncotarget 2017;8(56):95083–95094. DOI: 10.18632/oncotarget.18297.
145. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Impact of geographic accessibility on utilization of the annual health check-ups by income level in Japan: A multilevel analysis. PLoS ONE 2017;12(5):e0177091. DOI: 10.1371/journal.pone.0177091.
146. Nomura K, Kido M, Tanabe A, Nagashima K, Takenoshita S, Ando K. Investigation of optimal weight gain during pregnancy for Japanese Women. Scientific Reports 2017;7(1):2569. DOI: 10.1038/s41598-017-02863-1.
147. Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, Amata A, Sakao S, Nagashima K, Tatsumi K, Hiwasa T. Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies as a potential biomarker for cardiovascular and cerebrovascular events in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine 2017;13(3):393–400. DOI: 10.5664/jcsm.6488.
148. Koshizaka M, Ishikawa K, Ishikawa T, Kobayashi K, Takemoto M, Horikoshi T, Shimousa R, Takahashi S, Nagashima K, Sato Y, Tatsuno I, Terano T, Hashimoto N, Kuribayashi N, Uchida D, Yokote K, on behalf of the PRIME-V Study Investigators. Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in type 2 diabetes patients receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: A study protocol for a prospective, multicenter, blinded-endpoint phase IV randomized controlled trial (PRIME-V study). BMJ Open 2017;7(5):e015766. DOI: 10.1136/bmjopen-2016-015766.
149. Nishimura T, Iwasa S, Nagashima K, Okita N, Takashima A, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Boku N. Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. Gastric Cancer 2017;20(4):655–662. DOI: 10.1007/s10120-016-0670-9.
150. Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Akagi R, Yamaguchi T, Takahashi K, Nagashima K, Takahashi K. Quantitative US elastography can be used to quantify mechanical and histologic tendon healing in a rabbit model of achilles tendon transection. Radiology 2017;283(2):408–417. DOI: 10.1148/radiol.2016160695.
151. Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida K-I, Suzuki N, Nodera H, Tsuji S, Koike H, Kira J-I, Hanaoka H, Kusunoki S, Kuwabara S, JET-GBS Group. A prospective, multi-center, randomized phase II study to evaluate the efficacy and safety of eculizumab in patients with Guillain-Barré syndrome (GBS): Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Research Protocols 2016;5(4):e210. DOI: 10.2196/resprot.6610.
152. Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Sugimoto K, Nagashima K, Hanaoka H, Kobayashi Y. Efficacy of intravenous nicorandil for fractional flow reserve assessment: Study protocol for a crossover randomised trial. BMJ Open 2016;6(11):e012737. DOI: 10.1136/bmjopen-2016-012737.
153. Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, Ikeda S-i, Kohara N, Kanda T, Kira J-i, Hanaoka H, Kuwabara S, for the Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2016;15(11):1129–1137. DOI: 10.1016/S1474-4422(16)30157-0.
154. Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Pretreatment immune status correlates with progression-free survival in chemotherapy-treated metastatic colorectal cancer patients. Cancer Immunology Research 2016;4(7):592–599. DOI: 10.1158/2326-6066.CIR-15-0298.
155. Sasaki Y, Akasu T, Saito N, Kojima H, Matsuda K, Nakamori S, Komori K, Amagai K, Yamaguchi T, Ohue M, Nagashima K, Yamada Y. Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer. Cancer Science 2016;107(7):1006–1012. DOI: 10.1111/cas.12950.
156. Tanemura N, Uyama Y, Nagashima K, Suzuki T, Asahina Y, Kobayashi Y, Iyo M, Yokote K, Hanaoka H. Comparison of drug use between clinical practice and regulatory approval: results in older Japanese patients with rheumatoid arthritis, diabetes, high blood pressure, or depression. Therapeutic Innovation & Regulatory Science 2016;50(6):743–750. DOI: 10.1177/2168479016648731.
157. Yamaguchi T, Iwasa S, Nagashima K, Ikezawa N, Hamaguchi T, Shoji H, Honma Y, Takashima A, Okita N, Kato K, Yamada Y, Shimada Y. Comparison of panitumumab plus irinotecan and cetuximab plus irinotecan for KRAS wild-type metastatic colorectal cancer. Anticancer Research 2016;36(7):3531–3536. URL: http://ar.iiarjournals.org/content/36/7/3531.
158. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Income related inequality of health care access in Japan: A retrospective cohort study. PLoS ONE 2016;11(3):e0151690. DOI: 10.1371/journal.pone.0151690.
159. Tawada A, Chiba T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Arai M, Kanda T, Shinozaki M, Goto N, Nagashima K, Yokosuka O. Utility of prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with nucleos(t)ide analogues. Oncology 2016;90(4):199–208. DOI: 10.1159/000444392.
160. Yamamoto Y, Yamaguchi S, Sasho T, Fukawa T, Akatsu Y, Nagashima K, Takahashi K. Quantitative ultrasound elastography with an acoustic coupler for achilles tendon elasticity: measurement repeatability and normative values. Journal of Ultrasound in Medicine 2016;35(1):159–166. DOI: 10.7863/ultra.14.11042.
161. Naito S, Tanaka J, Nagashima K, Chang B, Hishiki H, Takahashi Y, Oikawa J, Nagasawa K, Shimojo N, Ishiwada N. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan. Epidemiology and Infection 2016;144(3):494–506. DOI: 10.1017/S0950268815001272.
162. Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A, on behalf of the KAICA Trial investigators. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). BMJ Open 2015;5(12):e009562. DOI: 10.1136/bmjopen-2015-009562.
163. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Validity assessment of self-reported medication use by comparing to pharmacy insurance claims. BMJ Open 2015;5(11):e009490. DOI: 10.1136/bmjopen-2015-009490.
164. Iwasa S, Nagashima K, Yamaguchi T, Matsumoto H, Ichikawa Y, Goto A, Yasui H, Kato K, Okita N, Shimada Y, Yamada Y. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. Cancer Chemotherapy and Pharmacology 2015;76(3):605–614. DOI: 10.1007/s00280-015-2834-4.
165. Fujita M, Sato Y, Nagashima K, Takahashi S, Hata A. Predictive power of a body shape index for development of diabetes, hypertension, and dyslipidemia in Japanese adults: a retrospective cohort study. PLoS ONE 2015;10(6):e0128972. DOI: 10.1371/journal.pone.0128972.
166. Utsumi H, Honma Y, Nagashima K, Iwasa S, Takashima A, Kato K, Hamaguchi T, Yamada Y, Shimada Y, Kishi Y, Nara S, Esaki M, Shimada K. Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer. Anticancer Research 2015;35(4):2255–2261. URL: http://ar.iiarjournals.org/content/35/4/2255.
167. Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Hamaguchi T, Shimada Y. Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Science 2015;106(5):604–610. DOI: 10.1111/cas.12642.
168. Nagashima K, Yanai T, Iwasa S, Ohyanagi F, Kasai T, Minato K, Sakai H, Sakamoto C, Takeda K, Harada D, Goto K, Yamamoto N. A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy. Japanese Journal of Clinical Oncology 2015;75(2):229–231. DOI: 10.1093/jjco/hyu191.
169. Shirakawa T, Kato K, Nagashima K, Nishikawa A, Sawada R, Takahashi N, Shoji H, Sasaki Y, Honma Y, Iwasa S, Takashima A, Okita N, Hamaguchi T, Yamada Y, Shimada Y. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology 2014;74(6):1207–1215. DOI: 10.1007/s00280-014-2597-3.
170. Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima S, Honma Y, Iwasa S, Kato K, Hamaguchi T, Shimada Y. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Science 2014;105(8):1002–1007. DOI: 10.1111/cas.12453.
171. Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Research 2013;33(1):309–316. URL: http://ar.iiarjournals.org/content/33/1/309.
172. Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K, Nakajima TE, Hamaguchi T, Shimada Y. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. International Journal of Clinical Oncology 2012;17(6):604–609. DOI: 10.1007/s10147-011-0331-2.
173. Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K. A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Investigational New Drugs 2012;30(5):2026–2031. DOI: 10.1007/s10637-011-9779-1.
174. Fujie H, Niu K, Ohba M, Tomioka Y, Kitazawa H, Nagashima K, Ohrui T, Numasaki M. A distinct regulatory role of Th17 cytokines IL-17A and IL-17F in chemokine secretion from lung microvascular endothelial cells. Inflammation 2012;35(3):1119–1131. DOI: 10.1007/s10753-011-9419-0.
175. Nakajima TE, Yoshida H, Okamoto N, Nagashima K, Taniguchi H, Yamada Y, Shimoda T, Masutomi K. Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma. Cancer Science 2012;103(2):233–238. DOI: 10.1111/j.1349-7006.2011.02142.x.
176. Tanai C, Nakajima TE, Nagashima K, Kato K, Hamaguchi T, Yamada Y, Muro K, Shirao K, Kunitoh H, Matsumura Y, Yamamoto S, Shimada Y. Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial. Journal of Oncology Practice 2011;7(3):148–153. DOI: 10.1200/JOP.2010.000106.
177. Hashimoto K, Takashima A, Nagashima K, Okazaki S, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. Journal of Cancer Research and Clinical Oncology 2010;136(7):1059–1064. DOI: 10.1007/s00432-009-0752-8.

Preprint(s)

1. Nagashima K, Noma H, Furukawa TA. pimeta: an R package of prediction intervals for random-effects meta-analysis. [arXiv:2110.07856]
2. Yuda S, Kato K, Sasaki Y, Takahashi N, Shoji H, Takashima A, Okita N, Honma Y, Iwasa S, Hamaguchi T, Nagashima K, Boku N. Risk factors for FN, mucositis and esophagitis of combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer. DOI: 10.21203/rs.3.rs-62898/v1.

著書 (翻訳書)

1. 佐藤俊太朗, 藤井亮輔, 芝孝一郎, 後藤匡啓, 今村文昭（監訳）, 莇生崇, 安富元彦, 石黒智恵子, 井上浩輔, 井上陽介, 岩上将夫, 遠藤彰, 大久保雄規, 大久保祐輔, 大沢樹輝, 大久敬子, 織田哲郎, 垣本啓介, 鍵山暢之, 苅谷瞳, 川添百合香, 木下喬弘, 小林鉄郎, 佐藤大輔, 鈴木越治, 空野すみれ, 高田大輔, 高橋孝幸, 高橋将宜, 武田祐介, 竹林由武, 田中仁啓, 田本光拡, 塘由惟, 長島健悟, 中島誉也, 西田一貴, 林岳彦, 藤井伽奈, 三谷知広, 三橋利晴, 山崎大, 芳川裕亮, 吉村聡志（訳）. 現代疫学 原著第4版. 学術図書出版社 2024. (Lash TL, VanderWeele TJ, Haneuse S, Rothman KJ (eds.) Modern Epidemiology, 4th Edition. Wolters Kluwer, 2020.) [Web Site]
2. 星野崇宏, 繁桝算男（監訳）, 猪狩良介, 宇佐美慧, 岡田謙介, 加藤諒, 篠崎智大, 篠田和彦, 清水祐弥, 高井啓二, 高田悠矢, 高橋耕史, 高畑圭祐, 長島健悟, 野間久史, 長谷川泰大, 福元健太郎, 二荒麟, 宮崎慧, 森川耕輔, 若野綾子（訳）．インベンス・ルービン 統計的因果推論（上・下）．朝倉書店 2023. (Imbens GW, Rubin DB. Causal Inference for Statistics, Social, and Biomedical Sciences: An Introduction. Cambridge University Press, 2015.) [Web Site: 上] [Web Site: 下]
3. 苅谷瞳, 西田典充, 齋藤雄介（監訳）, 馬場美彦, 麸沢美裕, 髙勇羅, 藤井亮輔, 浅野裕太, 小山佑奈, 山浦礼子, 谷拓朗, 川添百合香, 中村星斗, 西川寛来, 長島健悟, 茅野大志, 伏見淳, 平友樹, 佐藤俊太朗, 山口征啓, 中根優里, 堺琴美, 石原裕也（訳）. 疫学のためのRハンドブック. 2022. (Neale B, et al. The Epidemiologist R Handbook. 2021.) [Book Web Site]
4. 平川晃弘, 五所正彦（監訳）, 安藤英一, 佐藤泰憲, 高橋翔, 竹内久郎, 長島健悟, 中水流嘉臣, 野間久史, 藤井陽介, 松岡信篤, 松永信人, 丸尾和司, 山田将之（訳）. 臨床試験のための アダプティブデザイン. 朝倉書店 2018. (Chow SC, Chang M. Adaptive Design Methods in Clinical Trials, Second Edition. CRC Press, 2012.) [Web Site]
5. 五所正彦（監訳），佐藤泰憲，竹内久朗，長島健悟，中水流嘉臣，平川晃弘，松永信人，山田雅之（訳）．生存時間解析入門 原書第2版．東京大学出版会 2014．(Hosmer DW, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time-to-Event Data, 2nd. Editon. Wiley, 2008.) [Web Site]

原著論文 (和文)

1. 加藤直広, 野間久史, 長島健悟. 大規模推測における最適なランキングと選択の方法：ベイズ流階層混合モデリングの応用. 応用統計学 2019;32(2):105–117. DOI: 10.20551/jscswabun.32.2_105.
2. 菊地綾子, 平本秀二, 堀哲雄, 吉岡亮, 長島健悟. 終末期進行がん患者における長期入院の予測因子と終末期症状・治療との関連. Palliative Care Research 2018;13(4):335–340. DOI: 10.2512/jspm.13.335.
3. 大島新司, 間祐太朗, 長島健悟, 田中享, 佐野元彦, 太田昌一郎, 細谷治, 安野伸浩, 從二和彦. フェンタニル貼付剤の粘着性に関する検討―貼付試験と粘着性による評価―. 日本緩和医療薬学雑誌 2012;5:7–13.

総説・解説

1. 長島健悟, 十島玄汰, 佐藤泰憲. 推定：信頼区間とは. 医学のあゆみ 2025;294(2):197–204. DOI: 10.32118/ayu294020197.
2. 長島健悟, 尾崎達郎, 佐藤泰憲. 臨床研究の成果報告–CONSORTとSTROBEの紹介. 医学のあゆみ 2025;293(13):1242–1250. DOI: 10.32118/ayu293131242.
3. 長島健悟, 浮田翔子, 佐藤泰憲. 臨床試験のデザイン. 医学のあゆみ 2025;293(12):1165–1171. DOI: 10.32118/ayu293121165.
4. 長島健悟, 木村流星, 佐藤泰憲. ランダム化とは. 医学のあゆみ 2025;293(11):1097–1103. DOI: 10.32118/ayu293111097.
5. 長島健悟, 石田典之, 佐藤泰憲. 交絡とその制御方法. 医学のあゆみ 2025;293(8):705–710. DOI: 10.32118/ayu293080705.
6. 長島健悟, 十島玄汰, 佐藤泰憲. 観察研究の計画. 医学のあゆみ 2025;293(7):637–643. DOI: 10.32118/ayu293070637.
7. 長島健悟, 近藤雅大, 佐藤泰憲. 医学研究データの特徴とまとめ方. 医学のあゆみ 2025;293(6):552–559. DOI: 10.32118/ayu293060552.
8. 長島健悟, 佐藤泰憲. アダプティブデザインの基礎─実例とともに. 医学のあゆみ 2022;280(5):442–450. DOI: 10.32118/ayu28005442.
9. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学研究における生存時間データの統計解析. 日本小児アレルギー学会誌 2016;30(5):659–665. DOI: 10.3388/jspaci.30.659.
10. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学研究における統計モデル解析. 日本小児アレルギー学会誌 2016;30(4):580–586. DOI: 10.3388/jspaci.30.580.
11. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学研究における症例数設計. 日本小児アレルギー学会誌 2016;30(2):190–197. DOI: 10.3388/jspaci.30.190.
12. 佐藤泰憲, 長島健悟, 高橋翔. 医学・薬学データの統計解析I: 推定と検定. 日本小児アレルギー学会誌 2015;29(5):718–723. DOI: 10.3388/jspaci.29.718.
13. 佐藤泰憲, 長島健悟, 高橋翔. 疫学研究の計画: 研究デザインとデータ解析. 日本小児アレルギー学会誌 2015;29(3):312–317. DOI: 10.3388/jspaci.29.312.
14. 佐藤泰憲, 高橋翔, 長島健悟. 臨床試験の計画: 試験デザインとデータ解析. 日本小児アレルギー学会誌 2015;29(2):214–221. DOI: 10.3388/jspaci.29.214.
15. 五所正彦, 長島健悟, 佐藤泰憲. バイオマーカー探索的研究デザイン. 日本臨牀 2012;70(5):874–879.
16. 佐藤泰憲, 長島健悟, 浜田知久馬. 個別化医療のための研究デザインと統計解析法. 臨床薬理 2010;41(6):291–300. DOI: 10.3999/jscpt.41.291.

競争的資金等

生物統計学

1. 生存時間解析の方法論に関する統合的研究. 日本学術振興会：科学研究費補助金 基盤研究(C) 25K15024. 2025年4月–2029年3月. (研究代表者)
2. 変量効果モデルによるメタアナリシスにおけるモデル誤特定下での統計的推測. 日本学術振興会：科学研究費補助金 若手研究 19K20229. 2019年4月–2022年3月. (研究代表者)
3. ネットワークメタアナリシスにおける統計的推測・予測・モデリングの方法論の開発. 日本学術振興会：科学研究費補助金 基盤研究(B) 19H04074. 2019年4月–2020年3月. (研究分担者)
4. レアイベントデータに対する統計的推測と臨床研究への応用. 日本学術振興会：科学研究費補助金 若手研究(B) 16K16014. 2016年4月–2019年3月. (研究代表者)

臨床研究

5. 胃がん内視鏡検診でのAI併用が胃がん検出率を上昇させ、ダブルチェックの負担を軽減できるかの検証. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2025年4月–2028年3月. (研究分担者)
6. プラチナ併用療法に対して不応又は不耐となった進行期小腸腺癌に対するEnfortumab Vedotinの単群第II相試験. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2025年4月–2028年3月. (研究分担者)
7. 難治性食道がんの治療前生検を用いたサブタイプ分類に基づくPrecision Medicineに資する体外診断薬の開発. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2024年10月–2027年3月. (研究分担者)
8. 膵がん・大腸がんの発症リスク予測血液バイオマーカーの開発. 国立研究開発法人 日本医療研究開発機構：次世代がん医療加速化研究事業. 2024年4月–2026年3月. (研究分担者)
9. 外分泌機能推定による膵がん悪性化リスク層別化に有用な血液バイオマーカーの臨床開発. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2024年4月–2027年3月. (研究分担者)
10. 健康寿命延伸に備えた女性の心身の健康支援のための普及啓発に向けた研究. 厚生労働省科研費補助金：女性の健康の包括的支援政策研究事業. 2023年4月–2027年3月. (研究分担者)
11. 就労女性の性に関連する健康と労働生産性の実証研究. 全国健康保険協会：健康・医療情報を活用した委託研究事業. 2023年4月–2027年5月. (研究分担者)
12. 抗体基盤網羅的スクリーニングによる消化器がん早期診断バイオマーカーの開発. 国立研究開発法人 日本医療研究開発機構：次世代がん医療加速化研究事業. 2022年4月–2024年3月. (研究分担者)
13. 膵外分泌機能を評価する血液バイオマーカーを用いた膵がんリスク疾患・早期膵がんの診断法の臨床開発. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2021年4月–2024年3月. (研究分担者)
14. 難治性食道癌におけるPrecision Medicineに資する診断技術開発に関する研究. 国立研究開発法人 日本医療研究開発機構：次世代がん医療創生研究事業. 2021年4月–2023年3月. (研究分担者)
15. 胃癌の微量生検組織を用いたDNA修復能・がん抗原性解析による抗がん剤治療の最適化. 国立研究開発法人 国立国際医療研究センター：国際医療研究開発費 20A1014. 2020年4月–2023年3月. (研究分担者)
16. 情報通信技術を活用した子宮頸がん予防のヘルスリテラシー向上に関する研究. 日本学術振興会：科学研究費補助金 挑戦的研究 (萌芽) 19K22737. 2019年7月–2022年3月. (研究分担者)
17. 血液バイオマーカーを用いた効率的な膵がん検診の実用化. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2018年12月–2020年3月. (研究分担者)
18. 非小細胞肺がんの転移活性を評価し、術後補助化学療法の効果を予測するバイオマーカーの実用化に関する研究. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2017年4月–2020年3月. (研究分担者)
19. タンパク質・ペプチド修飾解析による早期がん・リスク疾患診断のための血液バイオマーカーの開発. 国立研究開発法人 日本医療研究開発機構：次世代がん医療創生研究事業. 2017年4月–2022年3月. (研究分担者)
20. 性差に基づく薬物療法の有効性・安全性の評価研究. 国立研究開発法人 日本医療研究開発機構：女性の健康の包括的支援実用化研究事業—Wise. 2016年11月–2019年3月. (研究分担者)
21. 膵がん検診の効率化を目指した血液バイオマーカーの実用化研究. 国立研究開発法人 日本医療研究開発機構：革新的がん医療実用化研究事業. 2016年9月–2017年3月. (研究分担者)

教育歴 (講義)

• 医学統計・医療情報. 慶應義塾大学医学部. 2022年–現在.
• 医学統計学. 慶應義塾大学大学院医学研究科. 2021年–現在.
• 臨床試験方法論. 慶應義塾大学大学院健康マネジメント研究科. 2019年–現在.
• 線形推測論. 東京理科大学大学院工学研究科. 2016年–現在.
• 公衆衛生学Ⅱ. 慶應義塾大学医学部. 2022年–2023年.
• 大学院特別講義. 日本医科大学大学院. 2022年.
• 経営工学特別講義. 東京理科大学大学院工学研究科. 2014年.
• 臨床研究入門. 千葉大学大学院医学薬学府. 2014年.
• 医薬統計概論. 千葉大学大学院医学薬学府. 2010年–2018年.
• 卒業実験. 城西大学薬学部. 2009年–2012年.
• 薬科学実習. 城西大学薬学部. 2008年–2013年.

ソフトウェア

• [R] gstest Package (Generalized Two-Sample Kolmogorov-Smirnov Test for Right-Censored Data)
• [R] surrosurvo Package (Evaluation of Individual-Level Surrogacy for Survival and Ordinal Endpoints)
• [R] RevGadgets Package as a contributor (postprocessing gadgets for output generated by RevBayes; CRAN Task View: Phylogenetics)
• [R] pimeta Package (prediction intervals for random-effects meta-analysis; Nagashima K, et al. Stat Methods Med Res 2019; CRAN Task View: MetaAnalysis)
• [R] ph2bayes Package (Bayesian Single-Arm Phase II Designs; CRAN Task View: ExperimentalDesign)
• [R] RcmdrPlugin.KMggplot2 Package (ggplot2 GUI frontend)
• [R] mmcm Package (Nagashima K, et al. Stat Appl Genet Mol Biol. 2011)
• [SAS] %skmdata macro (SAS macro for Kaplan-Meier plots with SGPLOT Procedure)
• [SAS] %stab macro (SAS macro for Table 1 and Cox regression models)
• [Web App] Sample Size Calculators

International Conferences

国内学会発表

統計

1. 近藤雅大, 長島健悟, 佐藤泰憲. 高頻度データの関数主成分スコアを補助変数として用いた多重補完法の提案. 日本計量生物学会年会, 2025年5月15日, 富山国際会議.
2. 木村流星, 長島健悟, 野村尚吾, 佐藤泰憲. 検定統計量のシフトを用いた再ランダム化検定ベースの信頼区間の提案. 統計関連学会連合大会, 2024年9月3日, 東京理科大学.
3. 近藤雅大, 長島健悟, 佐藤泰憲. 欠測により測定回数が不揃いな条件下でのrepeated measures correlationの提案. 日本計量生物学会年会, 2024年5月10日, 九州大学.
4. 長島健悟, 上蓑義典, 村田満, 長谷川直樹, 佐藤泰憲. Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination. 日本計量生物学会年会, 2023年4月21日, 北海道大学.
5. 長島健悟, 野間久史. 変量効果モデルによるメタアナリシスの予測区間. 統計関連学会連合大会, 2018年9月13日, 中央大学. [Slide]
6. 長島健悟. Information criteria for Firth's penalized partial likelihood approach in Cox regression models. 統計数理研究所リスク解析戦略研究センター 第9回 生物統計ネットワークシンポジウム, 2018年3月19日, FUKURACIA 丸の内オアゾ. [Slide]
7. 佐藤泰憲, 長島健悟. 個別化医療のための研究デザイン ～Enrichment Designを中心に～. 日本計算機統計学会 第27回大会, 2013年5月16日, 弘前大学創立50周年記念会館.
8. 長島健悟. Rパッケージの開発・登録とメンテナンス. 2010年度 統計数理研究所共同研究集会「データ解析環境 R の整備と利用」, 2010年11月25日–27日, 統計数理研究所. [Slide]
9. 長島健悟, 佐藤泰憲. Kaplan-Meier プロットに付加情報を追加するマクロの作成. SAS ユーザー総会, 2010年7月26日–27日, タワーホール船堀. [Report] [Slide]
10. 長島健悟. ゲノム網羅的解析における薬物動態関連遺伝子検出のためのスチューデント化修正最大対比法の提案. 統計数理研究所リスク解析戦略研究センター研究会, 2010年3月26日, 癌研究所. [Slide]
11. 長島健悟, 佐藤泰憲, Laird NM. ゲノムワイド関連解析における薬物動態関連遺伝子同定のための新しいスクリーニング法. SASユーザー総会, 2009年7月30日, タワーホール船堀. [Report]
12. 長島健悟, 堀尾浩史, 浜田知久馬. HWD 下での Fisher の正確検定の性能比較. 統計関連学会連合大会, 2007年9月7日, 神戸大学.

臨床試験・疫学・基礎

13. 野呂林太郎, 本田一文, 長島健悟, 元井紀子, 功刀しのぶ, 松林純, 武内進, 白石英晶, 岡野哲也, 渡辺俊一, 臼田実男, 池田徳彦, 清家正博, 弦間昭彦, 久保田馨. 肺腺がんの転移活性を評価し、術後補助化学療法の効果を予測するバイオマーカーの実用化に関する後ろ向き研究-多施設共同研究-. 第61回日本呼吸器学会学術講演会, 2021年4月23日–25日, Web開催.
14. 野村恭子, 藤田望, 太田友, 鎌塚真, 毛内悠絵, 酒井一樹, 鈴木智也, 南園佐知子, 平山純子, 長島健悟, 寺田幸弘. HPVワクチン接種行動の関連因子: 子宮頚がんおよびHPVワクチンに関する知識、ヘルスリテラシー、健康信念モデルの検討. 第91回 日本衛生学会 学術総会, 2021年3月9日–11日, 富山国際会議場, 富山.
15. 山根禎子, 中森聡美, 望月晴美, 池田真由美, 下茂慶子, 若桑恵子, 山下紀子, 吉田輝彦, 坂本裕美, 平岡伸介, 谷田部恭, 山本昇, 間野博行, 長島健悟, 加藤健. 国立がん研究センターバイオバンクへの協力非同意/偶発的所見の提供を希望しない患者の理由、背景とその解析. 日本人類遺伝学会第65回大会, 2020年11月18日–12月2日, Web開催.
16. 本田一文, 小林隆, 佐藤雄, 長島健悟, 加城歩, 武内恵子, 野村由美子, 小西宏, 吉田 優. ApoA2-isoforms血液バイオマーカースクリーニングによる膵がんリスク層別化. 第58回日本癌治療学会, 2020年10月24日, 国立京都国際会館, 京都.
17. 高橋直樹, 庄司広和, 高張大亮, 原浩樹, 江崎泰斗, 町田望, 長島健悟, 青木一教, 本田一文, 宮本敬大, 朴成和, 加藤健. NIVORAM試験におけるニボルマブ・ラムシルマブ併用療法の有効性とTMLとの関連性. 第92回日本胃癌学会総会, 2020年3月6日, パシフィコ横浜, 神奈川.
18. 本田一文, 小林隆, 小西宏, 長島健悟, 吉田優. 血液バイオマーカーによる効率的な膵がん検診法とリスク層別化の可能性. 第78回日本癌学会学術総会, 2019年9月28日, 国立京都国際会館, 京都.
19. 石川耕, 越坂理也, 石橋亮一, 前澤善朗, 坂本憲一, 内田大学, 中村晋, 山賀政弥, 横尾英孝, 大西俊一郎, 小林一貴, 荻野淳, 橋本尚武, 徳山宏丈, 大原恵美, 石川崇広, 正司真弓, 井出真太郎, 井出佳奈, 小林明菜, 馬場雄介, 高橋翔, 長島健悟, 佐藤泰憲, 竹本稔, 横手幸太郎. メトホルミンを対照としてイプラグリフロジンによる内臓脂肪面積の変化を検討した多施設共同無作為化比較試験PRIME-V Study. 第61回日本糖尿病学会年次学術集会, 2018年5月24日–5月26日, 東京国際フォーラム, 東京.
20. 中山季昭, 酒井洋, 矢内貴子, 橋本浩伸, 後藤悌, 瀧口友美, 大柳文義, 中尾將彦, 武田晃司, 新井隆広, 湊浩一, 鈴木賢一, 岩佐悟, 長島健悟, 山本昇. 制吐作用を目的としたオランザピン10mgと5mgの有効性と安全性を評価する用量設定試験. 第54回日本癌治療学会学術集会, 2016年10月20日–10月22日, パシフィコ横浜, 神奈川.
21. 中尾將彦, 吉田徹也, 矢内貴子, 橋本浩伸, 本永正矩, 瀧口友美, 大柳文義, 中山季昭, 齊藤こずも, 藤田行代志, 湊浩一, 鈴木賢一, 寺門浩之, 岩佐悟, 長島健悟, 山本昇. 高度催吐性化学療法施行時の悪心・嘔吐の予防に対するオランザピン10mgと5mgの有効性と安全性を評価する用量設定第2相試験. 第26回 日本医療薬学会年会, 2016年9月17日–9月19日, 国立京都国際会館・グランドプリンスホテル京都, 京都.
22. 岩佐悟, 濱口哲弥, 後藤昌弘, 岡崎俊介, 笹木有佑, 長井祐志, 浅見千佳, 長島健悟, 島田安博. 高齢者切除不能の進行・再発胃癌を対象としたS-1/CDDP療法の多施設共同第Ⅱ相試験. 第52回 日本癌治療学会学術集会, 2014年8月28日–8月30日, パシフィコ横浜, 神奈川.
23. 岩佐悟, 濱口哲弥, 後藤昌弘, 富所隆, 笹木有佑, 長井祐志, 浅見千佳, 長島健悟, 島田安博. 高齢者切除不能進行・再発胃癌を対象としたS-1/CDDP療法の多施設共同第II相試験. 第51回 日本癌治療学会学術集会, 2013年10月24日–10月26日, 国立京都国際会館・グランドプリンスホテル京都, 京都.
24. 山口達郎, 山田康秀, 岩佐悟, 松本寛, 市川靖史, 後藤歩, 安井久晃, 加藤健, 沖田南都子, 長島健悟, 島田安博. 進行・再発大腸がんのS-1/イリノテカン±ベバシズマブ療法 第II相試験の統合解析. 第51回 日本癌治療学会学術集会, 2013年10月24日–10月26日, 国立京都国際会館・グランドプリンスホテル京都, 京都.
25. 竜野真維, 加藤健, 本間義崇, 岩佐悟, 濱口哲弥, 山田康秀, 島田安博, 馬屋原博, 伊藤芳紀, 伊丹純, 長島健悟. 臨床病期 II/III 期食道がんに対する化学放射線療法における追加化学療法の意義について. 第66回日本食道学会学術集会, 2012年6月21日–6月21日, 軽井沢プリンスホテルウエスト, 長野.
26. 中谷祥恵, 長島健悟, 増井彩乃, 川口光朗, 又平芳春, 藤堂浩明, 杉林堅次, 古旗賢二, 和田政裕. N-アセチルグルコサミンの摂取は健常人の季節変動に伴う肌水分量の低下を抑制する. 第25回キチン・キトサンシンポジウム, 2011年8月30日–31日, 奈良県新公会堂, 奈良.
27. 徳永伸也, 沖田南都子, 江崎泰斗, 馬場英司, 坂井大介, 瀧内比呂也, 水沼信之, 長島健悟, 濱口哲弥, 加藤健. 切除不能進行・再発大腸がんに対する mFOLFOX6+BV stop and go 臨床第II相試験. 第8回日本臨床腫瘍学会学術集会, 2010年3月18日–3月19日, 東京ビッグサイト, 東京.
28. 堀田洋介, 山田康秀, 加藤健, 平島詳典, 秋吉宏平, 長島健悟, 中島貴子, 濱口哲弥, 島田安博. 切除不能大腸癌二次治療例に対する FOLFIRI + Bevacizumab 療法の臨床第 2 相試験 (AVASIRI study). 第8回日本臨床腫瘍学会学術集会, 2010年3月18日–3月19日, 東京ビッグサイト, 東京. (Poster)
29. 佐藤真樹, 上田秀雄, 長島健悟, 木村聡一郎, 寺尾哲, 青木富雄, 森本雍憲. 悪性腫瘍患者における感染性と非感染性発熱の識別モデルに関する検討. 日本薬学会 第129年会, 2009年3月26日–28日, グランドプリンスホテル京都, 京都市, 京都. (Poster)
30. 橋本堅治, 高島淳生, 長島健悟, 佐藤宏征, 岡崎俊介, 中島貴子, 加藤健, 濱口哲哉, 山田康秀, 島田安博. 切除不能・再発進行胃がんに対する二次化学療法における予後因子の検討. 第46回 日本癌治療学会総会, 2008年10月30日–11月1日, 名古屋国際会議場, 名古屋.

その他の情報

Editorial Role

• Associate Editor: Japanese Journal of Statistics and Data Science (2023年–)
• 編集委員: 計量生物学 (2023年–)

Journal Reviewer

Statistics Journal

• Statistics in Medicine
• Statistical Methods in Medical Research
• Journal of the Royal Statistical Society: Series C (Applied Statistics)
• Biometrical Journal
• Research Synthesis Methods
• The American Statistician
• Annals of the Institute of Statistical Mathematics
• Statistics in Biopharmaceutical Research
• Japanese Journal of Statistics and Data Science
• Biostatistics & Epidemiology
• BMC Medical Research Methodology
• Journal of Statistical Computation and Simulation
• Statistical Applications in Genetics and Molecular Biology
• Contemporary Clinical Trials Communications
• Stats

Medical Journal

• Nature Communications
• European Journal of Epidemiology
• BMJ Public Health
• Annals of Surgical Oncology
• Cancer Science
• Diabetes, Obesity and Metabolism
• Aging
• Esophagus
• Surgery Today
• Expert Review of Respiratory Medicine
• Epidemiology and Infection
• Sleep Medicine
• Trials
• PLoS ONE
• BMJ Open
• Nanomedicine
• Cancer Biomarkers
• Asia-Pacific Journal of Clinical Oncology
• Journal of Clinical Pharmacy and Therapeutics
• International Journal of Environmental Research and Public Health

Journals in Other Fields

• Entropy
• Behaviormetrika
• The Journal of Experimental Education
• Journal of the Royal Society Interface
• Distributed Ledger Technologies
• BMC Bioinformatics
• Mathematics

委員・学会活動等

• 日本医師会 倫理審査委員会 事前レビュー委員 (2024年5月–2026年3月)
• 慶應義塾臨床研究審査委員会 技術専門員 (2023年7月–現在)
• 日本計量生物学会 評議員 (2023年1月–2027年12月)
• 統計関連学会連合大会 運営委員 (2023年度–2024年度)
• 統計質保証推進協会 統計検定問題策定委員会第一分科会 委員 (2020年, 2022年)
• 日本計量生物学会 企画委員 (2019年4月–2023年3月)
• 鳥取大学医学部附属病院 臨床研究審査委員会 技術専門員 (2018年6月–2021年3月)

• 2022年計量生物セミナー 講演. 2022年12月7日, 中央大学.[PDF]
• 2021年計量生物セミナー 座長. 2022年1月21日, オンライン開催.[PDF]
• 2020年計量生物セミナー オーガナイザー・司会・講演. 2020年12月19日, オンライン開催.[PDF]

所属学会

• The International Biometric Society (2008年4月–現在)
• American Statistical Association (2011年5月–現在)
• 日本計量生物学会 (2008年4月–現在)
• 日本統計学会 (2009年6月–現在)
• 日本疫学会 (2021年1月–現在)

研究領域

• 生物統計学
• バイオインフォマティクス
• ゲノム疫学
• 母集団薬物動態学
• バイオマーカーの臨床試験・臨床研究
• がん化学療法の臨床試験・臨床研究

• 生存時間解析
• メタアナリシス
• 診断統計学
• 因果推論
• ベイズ推測
• モデル選択
• 欠測データ
• 高次元データ
• モデル誤特定
• セミパラメトリックモデル
• 混合効果モデル
• 推定方程式

学歴

• 1998年4月–2001年3月 埼玉県立浦和西高等学校 普通科
• 2002年4月–2006年3月 東京理科大学 工学部 経営工学科 学士（工学）
• 2006年4月–2008年3月 東京理科大学大学院 工学研究科 経営工学専攻 前期博士課程 修士 (工学)
• 2010年4月–2014年3月 東京理科大学大学院 工学研究科 経営工学専攻 後期博士課程 博士 (工学)

職歴

• 2008年4月–2013年3月 城西大学 薬学部 薬科学科 助手
• 2013年4月–2015年3月 千葉大学医学部附属病院 臨床試験部 特任助教
• 2015年4月–2018年3月 千葉大学大学院医学研究院 グローバル臨床試験学 特任助教
• 2018年4月–2021年3月 統計数理研究所 医療健康データ科学研究センター 特任准教授
• 2018年11月–2021年3月 慶應義塾大学医学部 客員准教授
• 2019年1月–2021年3月 慶應義塾大学医学部 講師（非常勤）
• 2019年9月–2021年8月 国立がん研究センター研究所 早期診断バイオマーカー開発部門 外来研究員
• 2021年4月–2023年3月 統計数理研究所 医療健康データ科学研究センター 客員准教授
• 2021年11月–2022年10月 国立がん研究センター研究所 創薬標的・シーズ探索部門 外来研究員
• 2016年4月–現在 東京理科大学大学院 工学研究科 非常勤講師
• 2021年4月–現在 日本医科大学 非常勤講師
• 2021年4月–現在 慶應義塾大学病院 臨床研究推進センター 生物統計部門 特任准教授
• 2023年7月–現在 国立がん研究センター研究所 がん治療学研究分野 外来研究員
• 2024年4月–現在 秋田大学大学院医学系研究科 非常勤講師

連絡先

• E-mail:

リンク

•  ORCID (0000-0003-4529-9045)
•  Google Scholar Citations
•  ResearchGate
•  Publons (ResearcherID)
•  Researchmap
•  PubMed
•  GitHub

座右の銘

• 毎日初めての事をしたいし、見たことのないものを見たいし、知らないことを知りたい。

Last updated date